July 20, 2017 / 12:20 PM / 2 months ago

BRIEF-U.S. FDA grants orphan-drug designation to Astellas

July 20 (Reuters) - Astellas Pharma Inc:

* U.S. FDA grants orphan-drug designation to Astellas for development of FLT3 inhibitor gilteritinib in acute myeloid leukemia Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below